Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL

Clinical trial NCT06033820 · UNKNOWN

Trial details

NCT number: NCT06033820
Sponsor: RenJi Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Diffuse Large B-cell Lymphoma Recurrent Diffuse Large B Cell Lymphoma Refractory

Start date: 2023-10-12
Primary completion: 2025-06-30
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.